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Introduction
Estrogen promotes the growth and survival of nor-
mal and cancerous breast epithelial cells by binding
and activating the estrogen receptor (ER). The acti-
vated receptor in turn binds to gene promoters in
the nucleus and activates many other genes responsi-
ble for cell division, inhibition of cell death, new
blood vessel formation and protease activity. An
increase in the proportion of cells that express ER is
found at both the earliest stages of breast precancer
and in approximately 70% of breast cancers (1).
There are three ways in which estrogen-dependent
processes important in the development and progres-
sion of the majority of breast cancers may be inter-
rupted (Figure 1). The ﬁrst is to interfere with the
binding of estrogen to the ER and/or to the pro-
moter elements of the genes it regulates. Selective ER
modulators such as tamoxifen and raloxifene act in
this manner. A second method is to reduce or elimi-
nate ER expression. This is exempliﬁed by fulve-
strant, a selective ER down-regulator, which works
by making less receptor available for binding to
estrogen. The most direct means is to simply reduce
the amount of estrogen by interfering with its pro-
duction, via ovarian ablation in premenopausal
women and use of aromatase inhibitors or inactiva-
tors (AIs) in postmenopausal women. Because of
their effectiveness, AIs are quickly becoming the
most frequently used antihormonal treatment for
breast cancer in postmenopausal women. Further,
AIs are now being tested in breast cancer prevention
trials.
Aromatase inhibitors are not without adverse
effects, which primarily stem from profound estrogen
depletion. Many women will turn to their internists
for advice about whether to take these drugs, as well
as help in preventing and managing adverse events.
The purpose of this article is to provide primary care
physicians with a basic understanding of AIs to help
facilitate these interactions.
What is an aromatase inhibitor
and how does it work?
Aromatase inhibitors and inactivators interfere with
the body’s ability to produce estrogen from andro-
gens by suppressing aromatase enzyme activity.
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SUMMARY
The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letroz-
ole have largely replaced tamoxifen as the preferred treatment for hormone recep-
tor – positive breast cancer in postmenopausal women. Approximately 185,000
new cases of invasive breast cancer are diagnosed yearly, and at least half of
these women are both postmenopausal and eligible for adjuvant therapy with AIs.
In addition, AIs are currently being tested as primary prevention therapy in large
randomised trials involving tens of thousands of women at increased risk for breast
cancer. Given the volume of use, internists will increasingly see postmenopausal
women who are taking or considering treatment with AIs. Physicians need to be
able to: (i) brieﬂy discuss the pros and cons of using a selective estrogen receptor
modulator such as tamoxifen or raloxifene vs. an AI for risk reduction and (ii) rec-
ognise and manage AI-associated adverse events. The primary purpose of this
review is to help internists with these two tasks.
Review Criteria
Expert opinion based on review of literature on
relevant clinical trials.
Message for the Clinic
Both tamoxifen and AIs are effective for the
adjuvant and neoadjuvant treatment of
postmenopausal breast cancer; the optimal choice
of drug is dependent on the characteristics of the
patient and tumour. Adverse events with both drug
classes are manageable. Adverse events associated
with tamoxifen include increased risk of uterine
cancers and thromboembolic events vs. an
increased incidence of vaginal dryness, loss of
libido, musculoskeletal pain and bone mineral
density loss with AIs. Promising studies of AIs in
the breast cancer prevention setting are ongoing.
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for the majority of circulating estrogen and is exqui-
sitely sensitive to changes in luteinising hormone
(LH). Following menopause, aromatase in fat and
muscle may be responsible for much of the circulat-
ing estrogen. Aromatase in highly estrogen-sensitive
tissues, such as the breast, uterus, vagina, bone,
brain, heart and blood vessels, provides local estro-
gen in an autocrine fashion (Figure 2). The aroma-
tase gene promoter in breast tissue is less sensitive
than the gene promoter in the ovary to ﬂuctuations
in LH but much more sensitive to increases in
inﬂammatory cytokines. Circulating inﬂammatory
cytokines increase with age, and breast tissue inﬂam-
matory cytokines increase with proliferative breast
disease and breast cancer. Thus, it comes as little sur-
prise that breast aromatase activity is increased in
proliferative breast disease and many cases of breast
cancer (2).
Three generations of AIs have been developed
(Table 1) (3–8). Each successive generation has been
associated with higher speciﬁcity for the aromatase
enzyme (Figure 3), fewer adverse events, and greater
suppression of aromatase activity. The utility of ﬁrst-
and second-generation AIs was limited by adverse
events, such as rash, fatigue, dizziness, ataxia, nausea
and vomiting, as well as by a lack of enzyme selectiv-
ity. Third-generation AIs are superior to earlier ver-
sions because they are associated with fewer adverse
events and greater suppression of aromatase activity.
There are two classes of third-generation AIs. Non-
steroidal AIs reversibly bind to the aromatase enzyme
and include anastrozole and letrozole. The steroidal
AI exemestane binds to aromatase irreversibly. All
third-generation AIs are administered orally on a
daily basis. Adverse events include hot ﬂushes, vagi-
nal dryness, loss of libido, fatigue, arthralgias, joint
stiffness and loss of bone mineral density with subse-
quent increased risk of fracture (9). In premenopau-
sal women, AIs have a limited ability to reduce
circulating estrogen. Unlike postmenopausal women,
premenopausal women have a large amount of
aromatase substrate present in the ovary. The exqui-
site sensitivity of the ovarian aromatase promoter to
gonadotrophins, which increase dramatically after AI
administration, makes AIs less effective in inhibiting
ovarian estrogen production. Thus, AIs are generally
not given to premenopausal women for breast cancer
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Figure 1 Schematic of metabolic pathways in an
ER-positive cell that can be affected by AIs. The left side
represents the active pathways and cellular responses under
normal estrogen control. The right side depicts the
blockade of pathways involving ERs and the resultant
cellular responses. AI, aromatase inhibitor; E2, estradiol;
ER, estrogen receptor; MAP, mitogen-activated protein;
PI-3, phosphoinositide-3; RTK, receptor tyrosine kinase;
SERD, selective estrogen receptor down-regulator; SERM,
selective estrogen receptor modulator
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Figure 2 Schematic of organs with substantial aromatase
activity
Table 1 Efﬁcacy of aromatase suppression by three
generations of AIs
Drug Dose % Inhibition
First generation
Aminoglutethimide (1,3) 1 g 91
Second generation
Fadrozole (100) 2 mg 82
Vorozole (5) 1 mg 93
Third generation
Letrozole (100,101) 2.5 mg 99
Anastrozole (100,102) 1 mg 97
Exemestane (100,103,104) 25 mg 98
AIs, aromatase inhibitors.
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suppress the rise in gonadotrophins and subsequent
increase in hormone levels (9).
Why do we need aromatase
inhibitors?
For women with newly diagnosed hormone receptor
positive ER+ cancers requiring systemic adjuvant
therapy, 5 years of tamoxifen reduces the relative
odds of recurrence by 40% and relative risk of death
from breast cancer by 34% (10). At 15 years this
equates to about a 12% absolute reduction in recur-
rence and a 9% absolute reduction in mortality, irre-
spective of nodal status. However, about a third of
women diagnosed with ER-positive breast cancer will
ultimately relapse despite adjuvant tamoxifen with or
without chemotherapy (10). Women with hormone
receptor-positive disease that has metastasised to
organ sites distant from the breast almost always
relapse following ﬁrst-line antihormonal therapy with
tamoxifen. More effective antihormonal treatment
for tamoxifen-resistant tumours are needed.
There is some evidence suggesting a worse out-
come with tamoxifen for women with ER-positive
tumours that lack progesterone receptor (PgR), and/
or exhibit overexpression of growth factor receptors
such as human epidermal growth factor receptors
1and 2 (EGFR and HER-2/neu) (11,12). The obser-
vation that prolonged administration of tamoxifen
may increase rather than decrease late recurrence
rates (13) may be due to tamoxifen’s ability to act as
a partial estrogen agonist in breast tissue under con-
ditions of growth factor receptor up-regulation,
which commonly occurs after prolonged tamoxifen
use (11,12). AIs appear to be more effective than
tamoxifen in ER-positive tumours regardless of PgR
or growth factor receptor status (14,15).
Treatment with AIs produce frequent and durable
responses in postmenopausal women previously trea-
ted with tamoxifen or endocrine ablative surgery,
and AIs are more effective than tamoxifen in produc-
ing responses and delaying progression in ﬁrst-line
treatment of metastatic disease (16). A recent meta-
analysis concluded that in women with metastatic
breast cancer, AIs show a survival beneﬁt when com-
pared with other endocrine therapy (17).
How are aromatase inhibitors
currently used?
The third-generation AIs are currently the preferred
ﬁrst-line treatment for metastatic hormone receptor-
positive tumours and have all been approved by the
US Food and Drug Administration for adjuvant use
in postmenopausal women before or after surgery for
ER-positive and/or PgR-positive breast cancer (18).
Although anecdotal responses have been observed in
women with ER- and PgR-negative tumours, in cur-
rent clinical practice, only postmenopausal women
with ER-positive and/or PgR-positive tumours are
selected for treatment with AIs (9,16). There are sev-
eral clinical studies evaluating the use of AIs in pre-
menopausal women combined with ovarian
Figure 3 Metabolic pathways differentially targeted by aromatase inhibitors (AIs)
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analogue. AIs are generally not used off-label for pre-
menopausal women except in special circumstances,
such as prior tamoxifen failure or medical contraindi-
cations to tamoxifen. When AIs are used in premeno-
pausal women they must be combined with surgical
or medical ovarian ablation. Results with AIs in the
adjuvant or neoadjuvant setting are detailed below.
Neoadjuvant therapy with aromatase inhibitors
vs. tamoxifen
Systemic treatment administered before deﬁnitive
surgery is termed neoadjuvant therapy and is often
used in women who have clinically involved nodes
or a tumour that is ‡ 3 cm. Under these circum-
stances the chance of occult metastatic disease is
high, and the chance of breast conservation with a
cosmetically acceptable outcome is low. Neoadjuvant
treatment both increases the chance of breast conser-
vation and promotes timely treatment of occult
metastases. Pathological response to neoadjuvant
chemotherapy is an important prognostic factor.
Women with a pathological complete response in
breast and lymph nodes to neoadjuvant chemother-
apy have as much as a 95%, 5-year distant,
disease-free survival (DFS) (19). Although pathologi-
cal complete response rates after neoadjuvant chemo-
therapy are in the 20% or higher range for hormone
receptor-negative tumours, they are rare with
tumours that are hormone receptor-positive.
Neoadjuvant trials with antihormone therapy have
generally shown that the chance of breast conserva-
tion is higher with AIs than tamoxifen and may be
higher for AIs than for chemotherapy in women with
hormone receptor positive tumours (19–22). In a
trial comparing neoadjuvant letrozole with tamoxi-
fen, the mammographic complete response rate with
letrozole, although very low, was still higher than
that observed for tamoxifen (20). In the Immediate
Preoperative Anastrozole, Tamoxifen or Combined
with Tamoxifen trial, women randomised to anas-
trozole alone were signiﬁcantly more likely to have
experienced sufﬁcient tumour regression to be eligi-
ble for breast-conserving surgery than women rando-
mised to tamoxifen or combined treatment (23).
Neoadjuvant antihormonal therapy with an AI is a
particularly attractive option for postmenopausal
women who wish to attempt breast conservation and
have strongly ER- and PgR-positive tumours that are
‡ 3 cm and have low proliferation rates.
Adjuvant therapy with aromatase inhibitors vs.
tamoxifen
Clinical trials of AIs as adjuvant therapy have fol-
lowed one of four approaches: (i) a head-to-head
comparison of tamoxifen vs. an AI; (ii) extended
adjuvant therapy following initial adjuvant therapy
(5 years of an AI after 5 years of tamoxifen); (iii)
switching to an AI for 2–3 years after 2–3 years of
tamoxifen and (iv) combination therapy using both
an AI and tamoxifen simultaneously. All AI
approaches except the simultaneous combination of
an AI and tamoxifen are associated with fewer breast
cancer-related events than tamoxifen alone.
Head-to-head comparisons of an aromatase
inhibitor and tamoxifen
The Anastrozole, Tamoxifen Alone or in Combina-
tion (ATAC) trial randomised more than 9000
women to 5 years of tamoxifen, anastrozole or both
agents in combination. The combination treatment
did not show a beneﬁt and is not discussed further.
Sixty-one per cent of women had no disease detected
in their lymph nodes (referred to as node negative)
at diagnosis. After 5 years of treatment, there was a
signiﬁcant improvement in DFS in the group of
women treated with anastrozole alone regardless of
tumour size, nodal status or use of adjuvant chemo-
therapy before the randomisation. There was a signif-
icant interaction with hormone receptor status:
women who had ER-positive but PgR-negative
tumours were likely to have a superior outcome with
anastrozole, whereas women with tumours that were
positive for both receptors did just as well with
tamoxifen as with anastrozole. The absolute improve-
ment in DFS with 5 years of anastrozole, compared
with 5 years of tamoxifen, was 2.5% (p ¼ 0.005).
The incidence of contralateral breast cancer was
reduced by 53% in women with hormone receptor-
positive tumours. No overall survival beneﬁt or sig-
niﬁcant reduction in deaths from breast cancer was
demonstrated for anastrozole in this study. However,
there appears to be an emerging survival beneﬁt for
women with ER-positive tumours who also had evi-
dence of tumour cells in their draining lymph nodes
(referred to as node positive) (24,25).
In the Breast International Group’s Femara-
Tamoxifen trial, also known as BIG 1–98, 5 years of
adjuvant letrozole was compared with 5 years of
tamoxifen in postmenopausal women with ER-posi-
tive and/or PgR-positive breast cancer. Eventually,
this trial was modiﬁed with the addition of two
treatment groups in which women were either
switched from tamoxifen to letrozole or from letroz-
ole to tamoxifen after the initial 2 years of treatment
(26). Approximately 8000 patients were randomised
to receive tamoxifen or letrozole as their initial ther-
apy. Fifty-nine per cent of women were node nega-
tive, and the median age was 61. At a median
follow-up of slightly more than 2 years, there was a
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ª 2007 The Author
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–2063signiﬁcant 3.4% absolute improvement in DFS with
letrozole compared with tamoxifen. Women with
PgR-positive and PgR-negative cancer appeared to
beneﬁt equally from letrozole compared with tamoxi-
fen. An approximate 50% reduction in risk of con-
tralateral breast cancer was observed. No signiﬁcant
overall survival beneﬁt was reported, although there
was a numeric reduction in deaths from breast can-
cer and an increase in deaths because of other causes
in the group treated initially with letrozole (26).
These results were recently updated analysing only
those women randomised to 5 years of letrozole vs.
placebo. At a median follow-up of 51 months there
continues to be a 3% absolute improvement in DFS
(18% relative reduction) following letrozole with no
improvement in overall survival (27).
The ongoing Tamoxifen Exemestane Adjuvant
Multi-institutional (TEAM) trial compares exemes-
tane with tamoxifen as ﬁrst-line adjuvant treatment.
The TEAM trial is designed to compare DFS in
patients treated with exemestane vs. tamoxifen at
2.75 years, and to compare DFS in patients treated
with 5 years of up-front exemestane vs. tamoxifen
for 2.5–3 years followed by 2–2.5 years of exemes-
tane. Enrolment was completed in January 2006
(n ¼ 9786). We are awaiting the efﬁcacy results of
this trial.
Aromatase inhibitors as extended endocrine
adjuvant therapy
Given the appreciable late recurrence rates in
women with ER-positive breast cancer following
5 years of adjuvant tamoxifen, the MA.17 trial was
designed to determine whether 5 years of letrozole
(after 5 years of adjuvant tamoxifen) would
improve DFS compared with placebo. At a median
follow-up of 2.4 years from the time of randomisa-
tion, letrozole improved DFS, compared with pla-
cebo, by a relative value of 43% and an absolute
value of 6%. This was signiﬁcant regardless of
nodal status (28). The trial was unblinded, with
women who received placebo given open-label
treatment with letrozole on request (28). In an
update of this study, a signiﬁcant reduction in
death from any cause was noted for node-positive
women receiving letrozole (29). Incidence of meno-
pause-related symptoms, new onset of osteoporosis,
arthralgias and alopecia (generally minimal to mild)
were all higher for women randomised to letrozole
compared with placebo. There was no increase in
the rate of bone fracture. There were some speciﬁc
quality of life domains which were signiﬁcantly
worse with letrozole, including physical functioning,
bodily pain, vitality, vasomotor symptoms and sex-
uality (30).
Switching therapy
The switching strategy was designed to: (i) combine
the apparent superior efﬁcacy of AIs with tamoxifen’s
favourable effects on bone and (ii) expose tumour
cells to anti-hormonal therapies with two different
mechanisms of action. Several adjuvant trials were
designed in which, after 2–3 years of adjuvant tamox-
ifen, women were randomised to continue taking
tamoxifen for another 2–3 years or switch to an AI.
One such trial, the Intergroup Exemestane Study
(IES), randomised 4742 postmenopausal women after
2–3 years of tamoxifen to exemestane 25 mg/day or
to continued tamoxifen of sufﬁcient duration to
complete a 5-year course of adjuvant therapy (31).
Fifty-one per cent of patients were node negative at
baseline, and 81% were known to have ER-positive
breast cancer. At a median follow-up of 30.6 months,
exemestane was associated with a 32% reduction in
risk of local or metastatic recurrence, contralateral
breast cancer, or death, for an absolute beneﬁt of
4.7% in terms of DFS compared with tamoxifen
(31). A recent update at 58 months showed similar
improvement in DFS in both the intent-to-treat
(24%) and ER-positive/unknown population (26%).
A 45% relative reduction in the incidence of contra-
lateral breast cancer was observed. A 17% relative
increase in overall survival (p ¼ 0.05) was reported
for women randomised to switch to exemestane
compared with those remaining on tamoxifen if their
tumours were ER-positive or ER unknown (32).
Quality of life measured at 3- to 6-month intervals
during the ﬁrst 24 months was similar for women
taking exemestane or tamoxifen (33).
In other switching trials, such as the Italian
Tamoxifen Arimidex (ITA) trial and the Austrian
Breast and Colorectal Study Group 8 (ABCSG 8)/
Arimidex-Nolvadex (ARNO 95) combined analysis,
switching to anastrozole after 2 years of tamoxifen
was compared with continued tamoxifen treatment.
A 39% relative improvement in DFS (p ¼ 0.049)
and 52% improvement in overall survival were seen
at a median follow-up of 30 months in the ABCSG
8/ARNO 95. Improvement in DFS was observed for
ITA (34,35).
In summary, all the adjuvant trials in postmeno-
pausal women – whether they involved initial head-
to-head comparison with tamoxifen (ATAC, BIG
1–98), switching to an AI after 2–3 years of tamoxi-
fen (IES, ITA and ABCSG 8/ARNO 95), or
administering 5 years of an AI after 5 years of
tamoxifen – show improvement in DFS favouring
the AI. An overall survival beneﬁt is emerging in at
least two of the switching trials in women rando-
mised to 2–3 years of an AI following 2–3 years of
tamoxifen vs. continuing on tamoxifen (32,35). No
Hormonal agents for treatment and prevention of breast cancer 2055
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strated to date for up-front AI administration with
letrozole or anastrozole or extended adjuvant therapy
with letrozole, although node-positive women appear
to show a survival beneﬁt. Follow-up in these trials
is short, and an overall survival advantage is likely
with up-front AI use. The lack of an early overall
survival advantage with AIs in the up-front setting
compared with the switch setting may be due to the
fact that the switch trials, by excluding women who
relapse on tamoxifen in the ﬁrst 2–3 years, enroll
women who are most likely to respond to antihor-
mone therapy. At present, the American Society of
Clinical Oncology Technical Assessment recommends
that postmenopausal women with receptor-positive
breast cancer receive an AI as part of their adjuvant
therapy, either as initial therapy, as part of a switch-
ing strategy, or after 5 years of tamoxifen (18).
There is no clear advantage to one AI vs. another
at the present time. Oncologists often select an AI
depending on the type of adjuvant strategy they wish
to employ. Several head-to-head trials comparing
one AI to another in the adjuvant setting are ongo-
ing. These include trials of anastrozole vs. exemes-
tane and anastrozole vs. letrozole.
Use of aromatase inhibitors in
premenopausal women
Responses have been observed in premenopausal
women with concomitant goserelin and AI treatment
following tamoxifen failure (36,37). This concept is
also being tested in the adjuvant setting with the
Suppression of Ovarian Function (SOFT) and
Tamoxifen or Exemestane Plus Ovarian Ablation
(TEXT) trials. In the SOFT trial, women who are
premenopausal after any adjuvant chemotherapy and
have ER-positive tumours are randomised to tamoxi-
fen, tamoxifen plus an LHRH analogue or exemes-
tane plus the LHRH analogue (other types of ovarian
ablation are also allowed). In the TEXT trial, pre-
menopausal women who may or may not have
received chemotherapy are randomised to receive
tamoxifen or exemestane, both with an LHRH ana-
logue. The TEXT trial is nearing completion of
accrual. It is not clear whether an AI with ovarian
ablation will be as good as or better than tamoxifen
with or without ovarian ablation at this time. If an
AI is given to a premenopausal woman outside of
these ongoing trials ovarian ablation with oophorec-
tomy or ovarian suppression with an LHRH ana-
logue must be given. If ovarian suppression with an
LHRH analogue is chosen, serum estradiol levels
must be monitored regularly to ensure that they
remain in the postmenopausal range.
Adverse event proﬁle of aromatase
inhibitors compared with tamoxifen
The adverse event proﬁle for AIs differs from that of
tamoxifen. There is no increase in uterine cancers or
thromboembolic events as is observed with tamoxi-
fen, but with the exception of hot ﬂushes. Women
taking AIs are more likely to complain of symptoms
related to estrogen deprivation. Women taking AIs
are also more likely to report musculoskeletal adverse
events than women taking tamoxifen. These are con-
sidered in detail below.
Gynaecological sequelae
Use of AIs is associated with a higher frequency of
vaginal dryness, loss of libido and painful intercourse
than is tamoxifen. There are fewer instances of vagi-
nal bleeding and endometrial cancer with AIs than
with tamoxifen (30,33,38). AIs are associated with
hot ﬂushes, but the proportion of women who exhi-
bit vasomotor instability may be less than that seen
with tamoxifen treatment (31,39). Younger age at
initiation of treatment is associated with increased
frequency of hot ﬂushes (40).
Musculoskeletal effects
Studies of tamoxifen in postmenopausal women have
shown reduction in bone turnover markers and an
increase in bone density and the opposite effects with
AIs (41–44). These differential effects are not surpris-
ing because tamoxifen exerts partial estrogen agonist
effects on bone in postmenopausal women, and oste-
oporosis has been strongly associated with the low
serum estrogen levels that occur following AI admin-
istration (45). Although a head-to-head comparison
of the three third-generation AIs in the Letrozole,
Exemestane, Anastrozole Pharmacodynamics study
has shown a similar effect on markers of bone turn-
over for all three drugs (46), it has also been sug-
gested that exemestane may be associated with less of
a deleterious effect than is seen with the other third-
generation AIs (47). Additional data are expected
from a bone substudy in MA.27, an adjuvant trial
comparing anastrozole with exemestane.
In adjuvant studies, all three third-generation AIs
– anastrozole, letrozole and exemestane – have
shown an increased risk of bone fracture compared
with tamoxifen. The absolute differences, while statis-
tically signiﬁcant in the ATAC trial of anastrozole vs.
tamoxifen and the BIG 1–98 trial of letrozole vs.
tamoxifen, were only 1–4%. Most fractures were in
the spine and not the hip (27,48). The difference in
fracture rate approached, but did not reach, statisti-
cal signiﬁcance in the IES trial (3.1% for women
switching to exemestane vs. 2.3% in women contin-
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after 5 years of tamoxifen had a numerically higher
fracture rate than placebo (5.3% vs. 4.3%), but like
the IES trial, the absolute excess fracture rate was
£ 1% and statistically insigniﬁcant (43). This would
seem to indicate that tamoxifen taken before an AI
provides some measure of bone mineral density pro-
tection in postmenopausal women.
Bisphosphonates can be used to prevent the bone
mineral loss observed with AIs. This strategy was suc-
cessfully used in the Zometa-Femara Adjuvant Synergy
trials, and the Austrian Breast and Colorectal Cancer
Study Group trial 12, in which an intravenous bis-
phosphonate, zoledronic acid, was administered every
6 months for the duration of AI therapy (49,50). Vita-
min D supplementation is advisable in women with
serum 25-OH vitamin D levels < 30 ng/ml because
women with baseline vitamin D insufﬁciency are at an
increased risk of bone loss when receiving AIs (51).
In randomised studies, arthralgias/myalgias have
been reported signiﬁcantly more frequently in
women randomised to AIs than in those randomised
to tamoxifen or placebo. The absolute frequency var-
ies tremendously from trial to trial (5.4–37% for AIs
vs. 3.6–26% for tamoxifen or placebo), which in turn
probably reﬂects the method used to record the
symptoms. The incidence of arthralgias and myalgias
appear to be about two-thirds higher with an AI
than with tamoxifen or placebo but usually improves
with time (38). Two small studies have shown that
women taking AIs for cancer therapy often have deﬁ-
cient or suboptimal 25-OH vitamin D levels in their
serum (51,52). Improvements in myalgias and arth-
ralgias were observed in a high proportion of women
with deﬁcient or suboptimal levels of vitamin D who
were given prescription-strength vitamin D for
12 weeks (52). Serum 25-OH vitamin D is used to
assess adequacy of total body vitamin D stores (53)
and levels should be checked prior to starting AI
treatment to make sure they are in the optimal range
of 30–50 ng/ml (53–55). In general, each additional
1000 IU of vitamin D3 can be expected to increase
25-OH-D serum levels by 10 ng/ml. The addition of
celecoxib 400 mg bid to exemestane reduced arthral-
gias and improved response rates in a placebo-con-
trolled trial in women with metastatic disease (56).
Prospective trials are under way to assess the preva-
lence of vitamin D deﬁciency in women undergoing
adjuvant therapy with AIs, correlation with the
development of myalgias/arthralgias and the relief of
symptoms with vitamin D replacement.
Thromboembolic and cardiovascular effects
Aromatase inhibitors do not increase the risk of deep
venous thrombosis; this differs from tamoxifen, for
which the risk of deep venous thrombosis and pul-
monary embolism is increased approximately twofold
(57,58). Further, except for a higher frequency of
occurrence in women over 50 and those with high
body mass index, there does not appear to be an eas-
ily identiﬁed predisposing factor behind the majority
of episodes of deep venous thrombosis associated
with tamoxifen (59).
Aromatase inhibitors in adjuvant trials have been
associated with an increase in ischaemic cardiovascu-
lar events and a numeric, but not statistically signiﬁ-
cant increase in cardiac deaths when compared with
tamoxifen (25,30,31), but not when compared with
placebo (29). AIs do not have a substantial effect on
lipid metabolism (39,58). It is possible that, if there
is an intrinsic adverse effect of AIs on ischaemic
heart disease, it might be due to estrogen depletion
in the coronary arteries leading to loss of the vasodi-
latory response of estrogen to stress (60). Alterna-
tively, the observation might stem from a small
cardio-protective beneﬁt from tamoxifen rather than
a deleterious effect of AIs. With the exception of tri-
glycerides, tamoxifen has a favourable effect on the
serum lipid proﬁle (1) and tamoxifen has also been
observed to improve endothelial function and reduce
carotid intima–media thickness in postmenopausal
women (61). Despite tamoxifen’s favourable effects
on some lipid and endothelial parameters, there is as
yet no conclusive evidence that tamoxifen exhibits
cardioprotective effects (62). The lack of signiﬁcant
cardiovascular beneﬁt in most randomised trials for
tamoxifen may be due to an increase in triglycerides
and clot promoting proteins, which offset the beneﬁ-
cial cardiovascular effects of tamoxifen (1,59). An
additional factor might be the widespread use of sta-
tins, which would obscure tamoxifen’s favourable
effects on cholesterol. In the ATAC trial, 4.1% of
participants randomised to anastrozole vs. 3.4% of
those randomised to tamoxifen died from ischaemic
heart disease (25). In the IES trial, at 3-year follow-
up, a higher number of cardiovascular deaths were
reported for exemestane than for tamoxifen (1.1%
vs. 0.8%) (31). In the BIG 1–98 trial, 2.5% of women
randomised to letrozole had serious or fatal cardiac
events compared with 1.1% taking tamoxifen; this
was highly signiﬁcant (27). There were also twice as
many cardiac deaths with letrozole than with tamoxi-
fen (13 vs. 6), but given the small number of events,
the difference was not statistically signiﬁcant.
Because the proportional differences in cardiac
deaths observed in women randomised to AI vs.
tamoxifen are < 1%, a potential increase in cardio-
vascular events is not likely to be a major concern
for women undergoing cancer therapy with an AI.
However, enthusiasm for AI use in the primary pre-
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associated with a higher number of cardiac events
compared with placebo or tamoxifen.
Management and prevention of
adverse events
As AI use becomes more common, internists will
undoubtedly be asked by their patients for help with
management and prevention of adverse events,
although the relative risks and beneﬁts of AIs vs.
other hormonal therapy will hopefully have been dis-
cussed by the patient’s oncologist.
For vasomotor symptoms, non-hormonal methods
such as selective serotonin reuptake inhibitors
(SSRIs), gabapentin or clonidine should be tried ﬁrst
(63). In doses commonly needed for relief of hot
ﬂushes (75 mg venlafaxine, 20 mg ﬂuoxetine and
300–900 mg gabapentin), side effects for these medi-
cations include drowsiness, dry mouth and dyspep-
sia. Use of SSRIs may also contribute to the loss of
sexual interest.
Vaginal dryness that is not ameliorated with lubri-
cants may be treated with poorly absorbed vaginal
estrogens, such as oestradiol vaginal rings or tablets.
However, a small study showed a signiﬁcant increase
in serum estrogen levels following use of these prepa-
rations (64). A weak preparation (1%) of testoster-
one with 2 mg of estriol (1 g administered 2–3 times
weekly) is often effective for improving vaginal dry-
ness, dyspareunia and libido. When women are tak-
ing AIs, testosterone cannot be readily converted to
estradiol. Estriol is a very weak estrogen and likewise
cannot be converted to estradiol (65). There is little
information regarding the safety of this practice, par-
ticularly in women with prior breast cancer (66).
Aromatase inhibitors for breast cancer
prevention
Tamoxifen fails to prevent ER-negative breast cancer,
and one-third or more of ER-positive breast cancers
(67–70). The incomplete efﬁcacy, increased risk of
serious adverse events, and the lack of survival bene-
ﬁt with tamoxifen given as primary prevention
(66–70) fuels the effort to develop safer and more
effective primary-prevention strategies. The superior
DFS observed for AIs compared with tamoxifen in
the adjuvant setting combined with the lack of
increase in thromboembolic events or uterine cancer
has led to the initiation of multiple primary-preven-
tion trials in high-risk women without prior breast
cancer. Currently, there are several major multi-insti-
tutional primary-prevention trials in postmenopausal
women in which an AI is being compared with
placebo (Table 2).
Of serious concern for prevention is the potential
for increase in risk of bone fracture and cardiovascu-
lar disease related to long-term estrogen depletion
with AIs. However, arthralgias, fatigue, dyspareunia,
reduced libido and hot ﬂushes may result in poor
uptake and/or compliance. Ongoing phase III preven-
tion trials will deﬁne the incidence of these adverse
events relative to placebo in a healthy population, and
potential solutions to avoid some of these problems
in the prevention setting are already being explored.
One small study indicates that bone mineral loss
after AIs is primarily limited to women with insufﬁ-
cient 25-OH vitamin D levels (71). Given the impor-
tance of adequate vitamin D in health, practitioners
should strive to achieve 25-OH vitamin D levels of
at least 30 ng/ml (55,72). Bisphosphonates have been
found effective in preventing AI- and cancer-ther-
apy-related bone mineral loss in the adjuvant setting
(73,74). Along with exercise and appropriate supple-
mentation of calcium and vitamin D, bisphospho-
nates could be used along with AIs to prevent bone
loss. Very low-dose estradiol (0.015 mg estradiol
patch replaced twice weekly) increased serum estra-
diol to a median of 12 pmol and may be effective in
reducing the increased bone turnover associated with
AI use (75).
Statins could be used along with AIs to improve
both lipid proﬁles and endothelial function. There is
Table 2 Ongoing Multi-institutional Phase III Primary Prevention trials of AIs in postmenopausal women
Trial Agents studied
Duration studied
(years)
International Breast Cancer Intervention Study II Anastrozole vs. placebo 5
Aromasin Prevention Study Exemestane vs. placebo 3
National Cancer Institute of Canada Clinical Trials
Group MAP.3 Breast Cancer Prevention Trial
Exemestane vs. placebo 5
AIs, aromatase inhibitors.
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statin might reduce breast cancer risk (76), but
results in case–control studies are mixed (77–79).
However, because both statins and AIs are metabo-
lised in the liver, pharmacological and pharmacody-
namical studies need to be completed to better
understand how concomitant administration might
affect levels of both drugs.
Approximately one-quarter of perimenopausal and
postmenopausal women take hormone replacement
therapy for some period of time during menopause
or menopause transition (80). Although other drugs
give partial relief of symptoms associated with the
climacteric, none is as effective as hormone replace-
ment (81). The Women’s Health Initiative (WHI)
indicates a nonsigniﬁcant increase in the risk of
breast cancer and coronary heart disease for women
taking combined oral equine estrogen plus a proges-
tin after 5 years. However, there was no increase in
breast cancer risk in the WHI for women taking
estrogen alone at a median follow-up time of
 7 years (82,83). In fact, updated results indicate
that women aged 50–59 randomised to estrogen
alone had a nonsigniﬁcant reduction in breast cancer
and coronary heart disease. Further, for women aged
50–59 randomised to estrogen alone or combined
estrogen plus progestin there was a signiﬁcant 30%
reduction in overall mortality compared with those
randomised to placebo (84,85). The Million Women
Study showed a modest increase in risk of breast
cancer for hormone replacement therapy given by
any route with the exception of vaginal hormones.
Similar to the WHI, women taking estrogen and a
progestin had a higher relative risk than those receiv-
ing estrogen alone (86). Few prevention options are
available for those women who need hormone
replacement for the management of menopausal
symptoms and who are at increased risk for breast
cancer because of family history or other factors.
Tamoxifen and hormone replacement (usually trans-
dermal) are commonly prescribed together in Eur-
ope, but this is generally not performed in the USA
(87). Furthermore, updated analyses of the three
major primary prevention trials of tamoxifen vs. pla-
cebo in which hormone replacement was allowed
have yielded conﬂicting results. The Italian preven-
tion trial conducted predominately in average risk
hysterectomised women found a reduced risk of ER+
breast cancer with tamoxifen only in those women at
increased risk because of hormone replacement or
other factors (69). The Royal Marsden trial showed a
reduced incidence of ER+ breast cancer whether
women took hormone therapy or not. However, the
International Breast Cancer Intervention Study 1 trial
results indicated tamoxifen was not effective in
women beginning hormone replacement therapy
(HRT) during study (68–70).
Preclinical studies indicate that AIs might be effec-
tive in reducing the risk of breast cancer in hormon-
ally intact animals under circumstances in which
breast aromatase is up-regulated (88). In studies of
postmenopausal women, breast estradiol levels have
been found to be 10- to 50-fold higher than serum
levels, and aromatase – which is up-regulated in pro-
liferative breast disease – is responsible for much of
this local synthesis (89,90). We have performed a
6-month pilot study of letrozole in high-risk women
who continued to take their hormone replacement
during the study period. An approximate two-thirds
reduction in breast tissue proliferation (Ki-67) was
observed after 6 months of letrozole. There was no
increase in hot ﬂushes or arthralgias for the majority
of women in the trial (91). The concept of using an
AI in women already receiving hormone replacement
therapy will be explored further in a placebo-con-
trolled, randomised, proof-of-principle trial in which
change in Ki-67 in benign breast tissue is the pri-
mary end-point. In this ongoing study, the change in
bone turnover markers and the cardiovascular risk
biomarkers will also be explored.
Overcoming resistance to aromatase
inhibitors
Even with an initial response to treatment, for women
with metastatic disease, resistance eventually develops
to AIs and clinical regrowth of tumour is observed. In
most cases, the resistant cancer continues to be ER
positive. There are several mechanisms of resistance
demonstrated in animal models. These include: (i)
development of hypersensitivity of the ER to very low
levels of estrogen; (ii) up-regulation of growth factor
receptors and/or associated signalling pathways
(HER-2, EGFR and insulin growth factor receptor
(IGFR)) (92,93). Reduction in the level of ER expres-
sion would theoretically reduce the sequelae of ER
hypersensitivity and could be accomplished by
increasing ER ubiquitisation with a drug such as ful-
vestrant, an ER down-regulator (94). Results from
animal models suggest that the AI letrozole plus fulve-
strant is more effective than either alone (93). Fulve-
strant is often effective as antihormonal therapy
following response and progression on an AI and is
equally effective as anastrozole in women with meta-
static disease who have previously been treated with
tamoxifen (94,95). Fulvestrant plus anastrozole is cur-
rently being compared with anastrozole alone in met-
astatic disease in the co-operative group setting. The
use of short courses of physiological or pharmacologi-
cal doses of estradiol to induce apoptosis in breast
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tumours are resistant to multiple types of endocrine
therapy including AIs has been suggested based upon
preclinical models (96,97). Combination regimens of
AIs and several types of growth factor receptor or acti-
vated pathway inhibitors are being explored (98–100).
Summary
The third-generation AIs are now preferred therapy
for postmenopausal women with hormone receptor-
positive tumours in both the early and metastatic
settings. Switching from adjuvant tamoxifen to an AI
(exemestane or anastrozole) after 2–3 years of
tamoxifen has shown superior DFS and overall sur-
vival compared with continuing on tamoxifen. Using
anastrozole or letrozole instead of adjuvant tamoxi-
fen as initial therapy (with or without prior adjuvant
chemotherapy) has also shown superior DFS. Finally,
for women completing 5 years of tamoxifen,
extended adjuvant antihormonal therapy with letroz-
ole has shown a reduced recurrence rate, particularly
for node-positive patients. American Society of Clini-
cal Oncology guidelines recommend that an AI be
included in a woman’s adjuvant regimen if she has
ER-positive and/or PgR-positive breast cancer. The
decision to use AI as initial endocrine therapy, as
opposed to switching to an AI after 2–3 years of
tamoxifen therapy, is likely to be guided by the
tumour characteristics. Patients who have ER-posi-
tive tumours with unfavourable characteristics, such
as HER-2 positivity, PgR negativity or nodal positiv-
ity, are likely to be selected for immediate AI ther-
apy. However, patients with ER-positive tumours
without unfavourable characteristics are likely to be
selected for tamoxifen treatment for 2–3 years before
taking an AI for 2–3 years. Several ongoing clinical
trials are examining the use of AIs in women at an
elevated risk of developing breast cancer. Critical to
the ultimate success of AIs in both the adjuvant and
preventive settings will be management of adverse
events, particularly bone mineral density loss, arthral-
gias and gynaecological sequelae.
Acknowledgements
Editorial support was provided by Complete Health-
care Communications, Inc., and was funded by Pﬁzer
Inc.
References
1 Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for
primary prevention of breast cancer. J Clin Oncol 2005; 23: 1644–
55.
2 Simpson ER, Davis SR. Minireview: aromatase and the regulation
of estrogen biosynthesis–some new perspectives. Endocrinology
2001; 142: 4589–94.
3 MacNeill FA, Jones AL, Jacobs S et al. The inﬂuence of amino-
glutethimide and its analogue rogletimide on peripheral aromati-
sation in breast cancer. Br J Cancer 1992; 66: 692–7.
4 Dowsett M, Stein RC, Mehta A, Coombes RC. Potency and selec-
tivity of the non-steroidal aromatase inhibitor CGS 16949A in
postmenopausal breast cancer patients. Clin Endocrinol (Oxf)
1990; 32: 623–34.
5 van der Wall E, Donker TH, de Frankrijker E et al. Inhibition of
the in vivo conversion of androstenedione to estrone by the
aromatase inhibitor vorozole in healthy postmenopausal women.
Cancer Res 1993; 53: 4563–6.
6 Dowsett M, Jones A, Johnston SR et al. In vivo measurement of
aromatase inhibition by letrozole (CGS 20267) in postmeno-
pausal patients with breast cancer. Clin Cancer Res 1995; 1:
1511–5.
7 Geisler J, King N, Dowsett M et al. Inﬂuence of anastrozole
(Arimidex), a selective, non-steroidal aromatase inhibitor, on in
vivo aromatisation and plasma oestrogen levels in postmeno-
pausal women with breast cancer. Br J Cancer 1996; 74: 1286–
91.
8 Geisler J, King N, Anker G et al. In vivo inhibition of aromatiza-
tion by exemestane, a novel irreversible aromatase inhibitor, in
postmenopausal breast cancer patients. Clin Cancer Res 1998; 4:
2089–93.
9 Winer EP. Optimizing endocrine therapy for breast cancer. J Clin
Oncol 2005; 23: 1609–10.
10 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview of the
randomised trials. Lancet 2005; 365: 1687–717.
11 Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict
adjuvant tamoxifen failure in patients with early breast cancer?
Eur J Surg Oncol 2001; 27: 335–7.
12 Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen
receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen
resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353–61.
13 Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than
ﬁve years of tamoxifen for lymph node-negative breast cancer:
updated ﬁndings from the National Surgical Adjuvant Breast and
Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:
684–90.
14 Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of
resistance to aromatase inhibitors. J Steroid Biochem Mol Biol
2005; 95: 167–72.
15 Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor prolifer-
ation more effectively than tamoxifen independent of HER1/2
expression status. Cancer Res 2003; 63: 6523–31.
16 Ingle JN, Suman VJ. Aromatase inhibitors for therapy of
advanced breast cancer. J Steroid Biochem Mol Biol 2005; 95:
113–9.
17 Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase
inhibitors for treatment of advanced breast cancer in postmeno-
pausal women. Cochrane Database Syst Rev 2007; CD003370.
18 Winer EP, Hudis C, Burstein HJ et al. American Society of Clini-
cal Oncology technology assessment on the use of aromatase
inhibitors as adjuvant therapy for postmenopausal women with
hormone receptor-positive breast cancer: Status Report 2004. J
Clin Oncol 2005; 23: 619–29.
19 Carey LA, Metzger R, Dees EC et al. American Joint Committee
on Cancer tumor-node-metastasis stage after neoadjuvant chemo-
therapy and breast cancer outcome. J Natl Cancer Inst 2005; 97:
1137–42.
20 Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treat-
ment of postmenopausal breast cancer patients with letrozole: a
randomized double-blind multicenter trial. Ann Oncol 2001; 12:
1527–32.
2060 Hormonal agents for treatment and prevention of breast cancer
ª 2007 The Author
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–206321 Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neo-
adjuvant endocrine therapy than tamoxifen for ErbB-1- and/or
ErbB-2-positive, estrogen receptor-positive primary breast cancer:
evidence from a phase III randomized trial. J Clin Oncol 2001;
19: 3808–16.
22 Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efﬁ-
cacy of neoadjuvant endocrine therapy vs chemotherapy in post-
menopausal women with ER- positive breast cancer. J Clin Oncol
2004; 22: 519.
23 Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of
postmenopausal breast cancer with anastrozole, tamoxifen, or
both in combination: the Immediate Preoperative Anastrozole,
Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter
double-blind randomized trial. J Clin Oncol 2005; 23: 5108–16.
24 Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimi-
dex, Tamoxifen, Alone or in Combination) trial after completion
of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;
365: 60–2.
25 Buzdar AU, Guastalla JP, Nabholtz JM et al. Impact of chemo-
therapy regimens prior to endocrine therapy: Results from the
ATAC (Anastrozole and Tamoxifen, Alone or in Combination)
trial. Cancer 2006; 107: 472–80.
26 Thurlimann B, Keshaviah A, Coates AS et al. A comparison of
letrozole and tamoxifen in postmenopausal women with early
breast cancer. N Engl J Med 2005; 353: 2747–57.
27 Coates AS, Keshaviah A, Thurlimann B et al. Five years of letroz-
ole compared with tamoxifen as initial adjuvant therapy for post-
menopausal women with endocrine-responsive early breast
cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486–92.
28 Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole
in postmenopausal women after ﬁve years of tamoxifen therapy
for early-stage breast cancer. N Engl J Med 2003; 349: 1793–802.
29 Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole
following tamoxifen as extended adjuvant therapy in receptor-
positive breast cancer: updated ﬁndings from NCIC CTG MA.17.
J Natl Cancer Inst 2005; 97: 1262–71.
30 Whelan TJ, Goss PE, Ingle JN et al. Assessment of quality of life
in MA.17: a randomized, placebo-controlled trial of letrozole
after 5 years of tamoxifen in postmenopausal women. J Clin
Oncol 2005; 23: 6931–40.
31 Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exe-
mestane after two to three years of tamoxifen therapy in post-
menopausal women with primary breast cancer. N Engl J Med
2004; 350: 1081–92.
32 Coombes R, Kilburn L, Snowdon C et al. Survival and safety of
exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment
(Intergroup Exemestane Study): a randomised controlled trial.
Lancet 2007; 369: 559–70.
33 Fallowﬁeld LJ, Bliss JM, Porter LS et al. Quality of life in the
Intergroup Exemestane Study: a randomized trial of exemestane
versus continued tamoxifen after 2 to 3 years of tamoxifen in
postmenopausal women with primary breast cancer. J Clin Oncol
2006; 24: 910–7.
34 Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastroz-
ole versus continued tamoxifen treatment of early breast cancer:
preliminary results of the Italian Tamoxifen Anastrozole Trial. J
Clin Oncol 2005; 23: 5138–47.
35 Kaufmann M, Jonat W, Hilfrich J et al. Survival beneﬁt of
switching to anastrozole after 2 years’ treatment with tamoxifen
versus continued tamoxifen therapy: the ARNO 95 Study. J Clin
Oncol 2006; 24: 547.
36 Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and
endocrine data for goserelin plus anastrozole as second-line
endocrine therapy for premenopausal advanced breast cancer.
Br J Cancer 2004; 90: 590–4.
37 Carlson R. Goserelin plus anastrozole for treatment of premeno-
pausal women with hormone receptor positive recurrent/meta-
static breast cancer [Abstract]. Breast Cancer Res Treat 2004; 88:
S237–8.
38 Fallowﬁeld L, Cella D, Cuzick J et al. Quality of life of postmeno-
pausal women in the Arimidex, Tamoxifen, Alone or in Combi-
nation (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;
22: 4261–71.
39 Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data
from clinical trials. J Steroid Biochem Mol Biol 2005; 95: 143–9.
40 Morales L, Neven P, Timmerman D et al. Acute effects of tamox-
ifen and third-generation aromatase inhibitors on menopausal
symptoms of breast cancer patients. Anticancer Drugs 2004; 15:
753–60.
41 Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces
bone turnover and prevents lumbar spine and proximal femoral
bone loss in early postmenopausal women. Bone Miner 1993; 22:
87–94.
42 Lonning PE, Geisler J, Krag LE et al. Effects of exemestane
administered for 2 years versus placebo on bone mineral density,
bone biomarkers, and plasma lipids in patients with surgically
resected early breast cancer. J Clin Oncol 2005; 23: 5126–37.
43 Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus
placebo on bone mineral density in women with primary breast
cancer completing 5 or more years of adjuvant tamoxifen: a com-
panion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629–
35.
44 Coleman R, Banks L, Girgis S et al. Skeletal effect of exemestane
in the Intergroup Exemestane Study (IES) 2 year bone mineral
density (BMD) and bone biomarker data [abstract 5076]. Breast
Cancer Res Treat 2005; 94: S233.
45 Chapurlat RD, Garnero P, Breart G et al. Serum estradiol and
sex hormone-binding globulin and the risk of hip fracture in
elderly women: the EPIDOS study. J Bone Miner Res 2000; 15:
1835–41.
46 McCloskey E, Hannon R, Lakner G et al. The letrozole (L), exe-
mestane (E), and anastrozole (A) pharmacodynamics (LEAP)
trial: a direct comparison of bone biochemical measurements
between aromatase inhibitors (AIs) in healthy postmenopausal
women. J Clin Oncol 2006; 24: 555.
47 Chien AJ, Goss PE. Aromatase inhibitors and bone health in
women with breast cancer. J Clin Oncol 2006; 24: 5305–12.
48 Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in com-
bination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early-stage breast can-
cer: results of the ATAC (Arimidex, Tamoxifen Alone or in Com-
bination) trial efﬁcacy and safety update analyses. Cancer 2003;
98: 1802–10.
49 Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledron-
ic acid prevents cancer treatment-induced bone loss in premeno-
pausal women receiving adjuvant endocrine therapy for
hormone-responsive breast cancer: a report from the Austrian
Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;
25: 820–8.
50 Brufsky A. Management of cancer-treatment-induced bone loss
in postmenopausal women undergoing adjuvant breast cancer
therapy: a Z-FAST update. Semin Oncol 2006; 33: S13–7.
51 Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid
metabolism in postmenopausal women with early breast cancer
after terminating 2-year treatment with exemestane: a rando-
mised, placebo-controlled study. Eur J Cancer 2006; 42: 2968–75.
52 Taylor M, Rastelli A, Civitelli R, Ellis M. Incidence of 25-OH
vitamin D deﬁciency in patients with a history of breast cancer
who have musculoskeletal symptomatology [Abstract]. Breast
Cancer Res Treat 2004; 88: S137.
53 Garland CF, Garland FC, Gorham ED et al. The role of vitamin
D in cancer prevention. Am J Public Health 2006; 96: 252–61.
54 Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ.
Human serum 25-hydroxycholecalciferol response to extended
oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–
10.
55 Heaney RP. Vitamin D requirement in health and disease. J Ste-
roid Biochem Mol Biol 2005; 97: 13–9.
Hormonal agents for treatment and prevention of breast cancer 2061
ª 2007 The Author
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–206356 Freyer G, Debled M, Geay JF et al. Celecoxib (Ce) + exemestane
(Ex) versus placebo + Ex in post-menopausal (PM) metastatic
breast cancer (MBC) patients (pts): a double-blind phase III
GINECO study. J Clin Oncol 2006; 24: 565.
57 Atalay G, Dirix L, Biganzoli L et al. The effect of exemestane on
serum lipid proﬁle in postmenopausal women with metastatic
breast cancer: a companion study to EORTC Trial 10951, ‘Ran-
domized phase II study in ﬁrst line hormonal treatment for met-
astatic breast cancer with exemestane or tamoxifen in
postmenopausal patients’. Ann Oncol 2004; 15: 211–7.
58 Bundred NJ. The effects of aromatase inhibitors on lipids and
thrombosis. Br J Cancer 2005; 93: S23–7.
59 Stamatelopoulos KS, Lekakis JP, Poulakaki NA et al. Tamoxifen
improves endothelial function and reduces carotid intima-media
thickness in postmenopausal women. Am Heart J 2004; 147:
1093–9.
60 Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vas-
cular and neoplastic events associated with tamoxifen. J Gen
Intern Med 2003; 18: 937–47.
61 Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene
on cardiovascular events and breast cancer in postmenopausal
women. N Engl J Med 2006; 355: 125–37.
62 Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects
of raloxifene: the arterial and venous systems. Am Heart J 2004;
147: 783–9.
63 Chlebowski RT, Kim JA, Col NF. Estrogen deﬁciency symptom
management in breast cancer survivors in the changing context
of menopausal hormone therapy. Semin Oncol 2003; 30: 776–88.
64 Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estra-
diol appears to be contraindicated in postmenopausal women on
adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584–7.
65 Bachmann GA, Leiblum SR. The impact of hormones on meno-
pausal sexuality: a literature review. Menopause 2004; 11: 120–30.
66 Somboonporn W, Davis SR. Testosterone effects on the breast:
implications for testosterone therapy for women. Endocr Rev
2004; 25: 374–88.
67 Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for pre-
vention of breast cancer: report of the National Surgical Adjuvant
Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:
1371–88.
68 Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen
prophylaxis for breast cancer – 96-month follow-up of the ran-
domized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272–82.
69 Veronesi U, Maisonneuve P, Rotmensz N et al. Tamoxifen for
the prevention of breast cancer: late results of the Italian Ran-
domized Tamoxifen Prevention Trial among women with hyster-
ectomy. J Natl Cancer Inst 2007; 99: 727–37.
70 Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year
follow-up of the Royal Marsden randomized, double-blinded
tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;
99: 283–90.
71 Lonning P, Geisler J, Krag LE et al. Vitamin D deﬁciency: a threat
to bone health in breast cancer patients during adjuvant treatment
with aromatase inhibitors. J Clin Oncol 2006; 24 (18S): 554.
72 Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney
RP. Vitamin D and calcium supplementation reduces cancer risk:
results of a randomized trial. Am J Clin Nutr 2007; 85: 1586–91.
73 Hillner BE, Ingle JN, Chlebowski RT et al. American Society of
Clinical Oncology 2003 update on the role of bisphosphonates
and bone health issues in women with breast cancer. J Clin Oncol
2003; 21: 4042–57.
74 Brufsky A, Bundred N, Coleman R et al. An integrated analysis
of zoledronic acid (ZA) for prevention of aromatase inhibitor
associated bone loss (AIBL) in postmenopausal women (PMW)
with early breast cancer (BCa) receiving adjuvant letrozole (LET).
Breast Cancer Res Treat 2006; 100 (Suppl. 1): S25 (abstract 107).
75 Kendall A, Smith I, Folkerd E, Dowsett M. Aromatase inhibition
and very low dose estradiol add-back: a pilot study for novel
breast cancer prevention [Abstract]. J Clin Oncol 2006; 24: 1014.
76 Campbell MJ, Esserman LJ, Zhou Y et al. Breast cancer growth
prevention by statins. Cancer Res 2006; 66: 8707–14.
77 Eliassen AH, Colditz GA, Rosner B et al. Serum lipids, lipid-low-
ering drugs, and the risk of breast cancer. Arch Intern Med 2005;
165: 2264–71.
78 Kumar AS, Esserman LJ. Statins: health-promoting agents show
promise for breast cancer prevention. Clin Breast Cancer 2005; 6:
455–9.
79 Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins
and breast cancer: a meta-analysis of seven randomized clinical
trials and nine observational studies. J Clin Oncol 2005; 23:
8606–12.
80 National Institutes of Health. National Institutes of Health State-
of-the-Science Conference statement: management of meno-
pause-related symptoms. Ann Intern Med 2005; 142: 1003–13.
81 Nelson HD. Commonly used types of postmenopausal estrogen
for treatment of hot ﬂashes: scientiﬁc review. JAMA 2004; 291:
1610–20.
82 Rossouw JE, Anderson GL, Prentice RL et al. Risks and beneﬁts
of estrogen plus progestin in healthy postmenopausal women:
principal results from the Women’s Health Initiative randomized
controlled trial. JAMA 2002; 288: 321–33.
83 Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated
equine estrogen in postmenopausal women with hysterectomy:
the Women’s Health Initiative randomized controlled trial. JAMA
2004; 291: 1701–12.
84 Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hor-
mone therapy and risk of cardiovascular disease by age and years
since menopause. JAMA 2007; 297: 1465–77.
85 Stefanick ML, Anderson GL, Margolis KL et al. Effects of conju-
gated equine estrogens on breast cancer and mammography
screening in postmenopausal women with hysterectomy. JAMA
2006; 295: 1647–57.
86 Beral V. Breast cancer and hormone-replacement therapy in the
Million Women Study. Lancet 2003; 362: 419–27.
87 Vogel VG. Reducing the risk of breast cancer with tamoxifen in
women at increased risk. J Clin Oncol 2001; 19: 87S–92.
88 Tekmal RR, Liu YG, Nair HB et al. Estrogen receptor alpha is
required for mammary development and the induction of mam-
mary hyperplasia and epigenetic alterations in the aromatase
transgenic mice. J Steroid Biochem Mol Biol 2005; 95: 9–15.
89 Ernster VL, Wrensch MR, Petrakis NL et al. Benign and malig-
nant breast disease: initial study results of serum and breast
ﬂuid analyses of endogenous estrogens. J Natl Cancer Inst 1987;
79: 949–60.
90 Santen RJ, Martel J, Hoagland M et al. Demonstration of aroma-
tase activity and its regulation in breast tumor and benign breast
ﬁbroblasts. Breast Cancer Res Treat 1998; 49 (Suppl. 1): S93–9;
discussion S109-19.
91 Fabian CJ, Kimler BF, Zalles CM et al. Reduction in proliferation
with six months of letrozole in women on hormone replacement
therapy. Breast Cancer Res Treat 2007; doi: 10.1007/s10549-006-
9476-5.
92 Jordan VC. SERMs: meeting the promise of multifunctional med-
icines. J Natl Cancer Inst 2007; 99: 350–6.
93 Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase
inhibitor studies. J Steroid Biochem Mol Biol 2007; doi: 10.1016/
j.jsbmb.2007.05.022.
94 Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus
anastrozole for the treatment of advanced breast carcinoma in
postmenopausal women: a prospective combined analysis of two
multicenter trials. Cancer 2003; 98: 229–38.
95 Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.
Additive antitumor effect of aromatase inhibitor letrozole and
antiestrogen fulvestrant in a postmenopausal breast cancer model.
Cancer Res 2005; 65: 5439–44.
96 Lønning PE, Taylor PD, Anker G et al. High-dose estrogen treat-
ment in postmenopausal breast cancer patients heavily exposed
to endocrine therapy. Breast Cancer Res Treat 2001; 67: 111–6.
2062 Hormonal agents for treatment and prevention of breast cancer
ª 2007 The Author
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–206397 Lewis JS, Meeke K, Osipo C et al. Intrinsic mechanism of estra-
diol-induced apoptosis in breast cancer cells resistant to estrogen
deprivation. J Natl Cancer Inst 2005; 97: 1746–59.
98 Marcom PK, Isaacs C, Harris L et al. The combination of letrozole
and trastuzumab as ﬁrst or second-line biological therapy produces
durable responses in a subset of HER2 positive and ER positive
advanced breast cancers. Breast Cancer Res Treat 2007; 102: 43–9.
99 Lane HA, Lebwohl D. Future directions in the treatment of hor-
mone-sensitive advanced breast cancer: the RAD001 (Everoli-
mus)-letrozole clinical program. Semin Oncol 2006; 33 (2 Suppl.
7): S18–25.
100 Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibi-
tors in the treatment of breast cancer. Endocr Rev 2005; 26: 331–45.
101 FEMARA  (Letrozole Tablets). Full Prescribing Information. East
Hanover, NJ: Novartis Pharmaceuticals Corporation, 2005.
102 ARIMIDEX  (Anastrozole Tablets). Full Prescribing Information.
Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.
103 Aromasin  (Exemestane Tablets). Full Prescribing Information.
New York, NY: Pharmacia & Upjohn Co., Division of Pﬁzer Inc.,
2005.
104 Brueggemeier RW. Overview of the pharmacology of the aroma-
tase inactivator exemestane. Breast Cancer Res Treat 2002; 74:
177–85.
Paper received May 2007, accepted August 2007
Hormonal agents for treatment and prevention of breast cancer 2063
ª 2007 The Author
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, December 2007, 61, 12, 2051–2063